Hasil Pencarian - Charles A. Schiffer

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use

    New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use oleh Charles A. Schiffer

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia – You can do this at home if you read the instructions

    Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia – You can do this at home if you read the instructions oleh Charles A. Schiffer

    Diterbitkan 2019-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

    Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia oleh Radhakrishnan Ramchandren, Charles A Schiffer

    Diterbitkan 2009-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia

    To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic... oleh Joshua T. Schiffer, Charles A. Schiffer

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? oleh Ehab Atallah, Charles A. Schiffer

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

    Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia oleh Roland B. Walter, Bruno C. Medeiros, Bayard L. Powell, Charles A. Schiffer, Frederick R. Appelbaum, Elihu H. Estey

    Diterbitkan 2012-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

    Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study oleh Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani

    Diterbitkan 2017-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

    Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia oleh Kathryn E. Flynn, Ehab Atallah, Li Lin, Neil P. Shah, Richard T. Silver, Richard A. Larson, Javier Panilla-Ibarz, James E. Thompson, Vivian G. Oehler, Jerald P. Radich, Vamsi Kota, Michael J. Mauro, Charles A. Schiffer, Jorge Cortes, Kevin P. Weinfurt

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

    Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia oleh Ehab Atallah, Charles A. Schiffer, Kevin P. Weinfurt, Mei-Jie Zhang, Jerald P. Radich, Vivian G. Oehler, Javier Pinilla-Ibarz, Michael W. N. Deininger, Li Lin, Richard A. Larson, Michael J. Mauro, Joseph O. Moore, Ellen K. Ritchie, Neil P. Shah, Richard T. Silver, Martha Wadleigh, Jorge Cortes, James Thompson, Jessica Guhl, Mary M. Horowitz, Kathryn E. Flynn

    Diterbitkan 2018-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: